Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

Stockholders' Equity
9 Months Ended
Apr. 30, 2013
Stockholders' Equity Note Disclosure [Text Block]

Note 7 – Stockholders’ Equity

Controlled Equity Offering

On March 28, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $20.0 million (the “Shares”). The Company will pay Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares will be issued pursuant to the Company’s Registration Statement which was declared effective on August 5, 2010 and the prospectus supplement, dated March 28, 2013, filed by the Company with the Securities and Exchange Commission. During the quarter ended April 30, 2013, the Company sold an aggregate of 72,487 shares of common stock under the Sales Agreement at an average price of $2.18 per share. Proceeds of $0.2 million which were received by May 3, 2013 are included in prepaid expenses and other in the balance sheet as of April 30, 2013.

Share-based compensation

The Company has an incentive stock option plan (the “1999 Plan”), an incentive stock option and restricted stock award plan (the “2005 Plan”), and a long term incentive share award plan, (the “2011 Incentive Plan”), which are more fully described in Note 9 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2012. The 2011 Plan, which is the only plan from which awards may now be granted, provides for the award to eligible employees, officers, directors, consultants and other persons of stock options, stock appreciation rights (SARs), restricted stock, restricted stock units, performance awards, and other stock-based awards.

The amounts of share-based compensation expense recognized in the periods presented are as follows:

    Three months ended
April 30,
    Nine months ended
April 30,
    2013     2012     2013     2012  
Stock options     46             61        
Restricted stock     94       168       380       595  
    $ 140     $ 168     $ 441     $ 595  

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

    Three months ended
April 30,
    Nine months ended
April 30,
    2013     2012     2013     2012  
Cost of clinical laboratory services   $ 2     $ 3     $ 7     $ 8  
Research and development     1       1       2       4  
Selling, general and administrative     137       164       432       583  
    $ 140     $ 168     $ 441     $ 595  

0 excess tax benefits were recognized during the three and nine month periods ended April 30, 2013 and 2012.

Stock option plans

The following table summarizes stock option activity during the nine month period ended April 30, 2013:

    Options     Weighted
Value (000s)
Outstanding at July 31, 2012     736,490     $ 14.53                  
Awarded     336,817     $ 2.88                  
Exercised         $                  
Cancelled     (346,662 )   $ 11.82                  
Outstanding at end of period     726,645     $ 10.39       2.9 years     $  
Options vested at end of period     389,828     $ 2.88        1.2 years     $  

On January 17, 2013, the Company awarded 336,817 options to directors and certain officers with an exercise price of $2.88 and a five year term, of which 247,672 options vest over two years and 89,145 vest over three years. The weighted average assumptions used to fair value this option award were as follows: expected life of 3.3 years, expected volatility 60.8%, risk free interest rate of 0.45% and 0 dividend yield. As of April 30, 2013, 0 of these options were vested.

As of April 30, 2013, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $0.4 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is 1.9 years.

Restricted Stock Awards

A summary of the activity pursuant to the Company’s restricted stock awards for the nine months ended April 30, 2013 is as follows:

    Awards     Weighted
Award Price
Unvested at July 31, 2012     257,583     $ 3.58  
Awarded     37,000     $ 1.75  
Vested     (99,137 )   $ 2.91  
Forfeited     (11,667 )   $ 3.45  
Unvested at end of period     183,779     $ 3.58  

The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2013, there was approximately $0.3 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of approximately one year.

The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 2,322,000 shares as of April 30, 2013.